Okyanos Heart Institute Hosts Networking Reception for the International Stem Cell Society (STEMSO) World Conference in Freeport
Freeport, Bahamas (PRWEB) February 11, 2014 -- Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy, announces the company will host a “hard hat” reception for conference attendees at their new facility in Freeport. The conference, titled “Bridging the Gap: Research to Point of Care”, brings together medical scientists, clinicians, regulatory experts, and investors to discuss progress in the field of research and clinical protocols and the process of taking promising therapies to fight chronic disease to market in a responsible manner. Gold Sponsor Okyanos Heart Institute hosts a networking reception for conference attendees at their facility in Freeport on Friday, February 21st from 5:00 – 7:00 p.m. The company is calling the reception a “hard hat” reception metaphorically as the construction is not yet completed.
Chief Medical Officer Howard Walpole, M.D., M.B.A., F.A.C.C., F.S.C.A.I. and Chief Science Officer Leslie Miller, M.D., F.A.C.C. will host the reception, along with CEO Matthew Feshbach and offer tours of the commercial cath lab which will offer stem cell therapy to qualified patients with advanced coronary artery disease under the new laws and regulations in The Bahamas.
Douglas Hammond, president of STEMSO, states, “STEMSO will continue to provide a proactive and positive voice for organizations and jurisdictions using adult stem cells for therapies and transplants. The Commonwealth of The Bahamas, and our Gold Sponsor Okyanos Heart Institute provide an excellent example of the results that can be brought about with realistic, modern and balanced regulations that serve the national economic interest, patient needs for life-saving medicine and the business advantages for commercialization and translation of adult stem cells.”
“The reception in our facility will showcase the capabilities in The Bahamas to deliver high quality healthcare to patients in need,” says Walpole. “It will also provide an informal forum for relevant discussion on bridging the gap between research and point of care between scientists, regulatory experts, clinicians and government officials, and help to address issues of paramount importance such as patient safety and effective tracking of progress once the patients return home. We are proud to host this reception at Okyanos Heart Institute.”
“Treating patients with adipose-derived stem and regenerative cells (ADRCs) is showing existing promise in clinical trials,” states Leslie Miller, M.D., F.A.C.C. an investigator in more than eighty clinical trials for heart failure. “The next step in delivering stem cells to patients outside of clinical trials is close. I am enormously excited about the opportunity with this conference to engage in meaningful discussion around what parameters must exist to treat heart failure patients safely and tracking the effectiveness of these new options, which previously were unavailable to patients who have had heart attacks and/or stents, and who continue to worsen after exhausting all other interventions available to them.”
The complete agenda for the conference can be found on STEMSO’s website at http://www.stemso.org. Other speakers include stem cell researchers, scientists and practitioners from around the world with leading discoveries in the field, and investors in the healthcare space.
Registration is open for attending and exhibiting on STEMSO’s website.
About Okyanos Heart Institute: (Oh – key – AH – nos)
Based in Freeport, The Bahamas, Okyanos Heart Institute’s mission is to bring a new standard of care and a better quality of life to patients with coronary artery disease using cardiac stem cell therapy. Okyanos adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment utilizes a unique blend of stem and regenerative cells derived from one’s own adipose (fat) tissue. The cells, when placed into the heart via a minimally-invasive catheterization, stimulate the growth of new blood vessels, a process known as angiogenesis. The treatment facilitates blood flow in the heart and supports intake and use of oxygen (as demonstrated in rigorous clinical trials such as the PRECISE trial). The literary name Okyanos (“Oceanos”) symbolizes flow. For more information, go to http://www.okyanos.com.
Okyanos LinkedIn Page:
http://www.linkedin.com/company/okyanos-heart-institute
Okyanos Facebook Page:
https://www.facebook.com/OKYANOS
Okyanos Twitter Page:
https://twitter.com/#!/OkyanosHeart
Okyanos Google+ Page:
https://plus.google.com/+Okyanos/posts
Okyanos You Tube Physician Channel:
http://www.youtube.com/user/okyanosforphysicians
END
###
Erika Rosenthal, Okyanos Service Company, http://www.okyanos.com, +1 (855) 659-2667, [email protected]
Share this article